Current articles and info about your health

Friday, 25th July 2008

   home     about     authors     news     books     xml feed     sitemap     privacy     contact us

There are 11 users online

add to favorites
 make home page


Addiction Issues
 Aging
 Allergies & Sinuses
 Alternative Medicine
 Beauty & Health
 Books & Reading
 Common Illnesses
 Community Service
 Diabetic Health
 Dieting
 Diseases
 Environmental Health
 Exercise and Fitness
 Health Education
 Health Industry
 Health Insurance
 Health Legal Issues
 Health Technology
 Healthcare Services
 Healthy Eating
 Medical Equipment & Products
 Men's Health
 Mental and Emotional Health
 Muscle & Back Pain
 Nutrition and Supplements
 Pediatrics
 Pet Health
 Physical Therapy & Massage
 Prevention Health
 Vision Health
 Weight Management
 Women's Health

Our Newsletter

Sign up for our free
Health-Informant.com Ezine
Get all the latest Health news delivered right to your mailbox.

First Name:

Your Email:



We will never rent, share or sell your name to anyone else... ever! We respect your privacy!
  Other Resources


For other sources of health news, tips, and information, visit our resources page

 

  Submit an Article


Would you like to have your article posted? Click Here
 

 
 

Immunitor to collaborate with Russian biotech giant Vector
Added: 12/20/2003
 Type: Summary
 Viewed: 889 time(s)
 [ Not Rated Yet ]
How would you rate this article:    Bad Good   Go » 
Immunitor to collaborate with Russian biotech giant Vector

Thai-US vaccine company, Immunitor Corporation, exchanged letters of intent with VECTOR – the State Research Center of Virology and Biotechnology, Russian Federation Ministry of Health, Koltsovo, Novosibirsk region, Russia.

Both parties have expressed interest in joint development of orally delivered vaccines for a variety of viral diseases. This initiative originates from ongoing collaboration between Russian and Thai scientists in developing the new generation of smallpox vaccines as part of the international effort against bioterrorism. In addition to these goals other infectious diseases of concern to the public health will be investigated. The immediate targets of particular interest to both companies are HIV/AIDS, malaria, TB, and SARS. Vector has recently developed a laboratory diagnostic kit for SARS, which was based on the public database of coronaviruses’ genome sequence and will be capable to rapidly expand virus production on a commercial scale to satisfy needs for inactivated vaccine manufacture. Pursuant to the aims of letters of intent the plan for setting up a vaccine plant in Siberia is currently being discussed as the possible logical outcome of this partnership.

Russian government’s State Research Center of Virology and Biotechnology VECTOR also known as Vector was established in 1974 Vector has been pursuing various basic and applied research activities aimed at the development and manufacture of novel therapeutic, diagnostic, and vaccinal preparations against virus diseases. Professor Lev S. Sandakhchiev, the Director General of Vector, noted that ‘Considering the synergistic interest in this area and ongoing collaboration between Vector and Immunitor researchers this project will have significant impact on the future of vaccine industry and global health crisis. We have been working on mucosal immunization approach ourselves and the technology developed by Immunitor is promising as simple but effective means of vaccine delivery’.
Article Pages:  1  



  Article Comments   Add Comment | View All (0)
    There are currently no comments for this article.


All content © 2008 Webmaster, Immunitor to collaborate with Russian biotech giant Vector :: Health-Informant.com.